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LETTERS TO THE EDITORRegarding “A multilayer stent in the aorta may not seal
the aneurysm, thereby leading to rupture”
Lazaris and colleagues report the ﬁrst case of aortic rupture
after implantation of a ﬂow-diverting stent (FDS) in abdominal
aortic aneurysms (AAAs).1 There are now clinical, biological, and
radiological data establishing that intraluminal thrombus (ILT)
may be one of the driving forces in the evolution of dilation toward
ruptures of AAAs. ILT is a main source of proteases and oxidation
in AAAs as it is involved in the activation of plasmin and the reten-
tion of neutrophils. ILT is also a potential site of weak pathogen
contamination.2 The pathogenic spatiotemporal role of an ILT is
directly linked to its permanent renewal at the luminal interface
with circulating blood and to the high porosity of this neotissue,3
allowing pressure-dependent outward radial convection of prote-
ases and oxidized molecular mediators toward the arterial wall.
In contrast, occlusive thrombi are usually recolonized from
the adventitia by neovessel, allowing myoﬁbroblast spreading and
healing. Therefore, ﬁbrin-rich thrombi could be both a good
substrate for healing and a deleterious source of proteases in
AAAs. The pathogenic role of blood supply to the ILT is exempli-
ﬁed by the possible deleterious evolution of type II endoleaks after
endovascular repair (EVAR) and of partially thrombosed false
lumen as compared with complete thrombosis or patent false
lumen in type B aortic dissections.4 Indirect type II endoleaks
lead to a persistent interface between circulating blood and ILT,
potentially detrimental to AAAs. Therefore, lumbar and sacral
arteries must be embolized when an AAA is still growing after
an EVAR.5 Type IV endoleaks, because of the acquired porosity
of the graft, were also reported.6 Late reinterventions have been
also described in this situation.
The FDS is another example of this dual-potential evolution.
The multilayer noncovered FDS is able to “reduce ﬂow velocity in
the aneurysm vortex while improving laminar ﬂow in the main
artery,” leading or not leading to ILT exclusion.7 Moreover, the
FDS does not prevent transmission of intraluminal pressure through
the ILT to the aneurysmal wall.8 In their case report, Lazaris and
colleagues1 reasonably underline the fact that the aneurysmal sac
continues to be supplied by circulating blood at a low shear rate.
This continuous blood supply through the FDS allows the renewal
of ILT biological activities ﬁnally leading to rupture. The paradigm
of this technology is tomaintain aortic branch permeability, the bio-
logical risk of maintaining blood supply to the ILT.
Similar delayed rupture has also been reported with the use of
FDSs in cerebral aneurysms.9 Unfortunately, ﬂow diversion is not
always ILT biological exclusion. ILT exclusion is dependent on
both the morphology of the aneurysm and the composition of the
ILT. It is probably easier to exclude saccular aneurysms with a small
neck than fusiform aneursyms with a large interface with circulating
blood. This is probably the limit of these new devices for EVAR
whatever the localization of the aneurysm. Lazaris and colleagues1
reasonably state that “[f]urther laboratory and in vivo animal studies
might be needed.” These experimental approaches must be focused
on the evolution of the ILT under ﬂow diversion (healing vs
enhancement of detrimental biological activities), taking into
account the limits of the experimental models.
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Reply
Michel and colleagues enlighten us on the molecular biology
underlying aneurysm rupture, from which arise their consider-
ations with respect to multilayer ﬂow diverting stents (FDSs).1
Similarly, we add our skepticism about the efﬁciency and indica-
tions for use of this novel technique of endovascular treatment
of aortic aneurysms. From the limited data available in the current
literature, it seems that although FDSs provide blood ﬂow diver-
sion from the aneurysm sac into the side branches of the aneurysm,
they do not cause complete cessation of the ﬂow inside the sac, at
least for the ﬁrst few months after their implantation.2 On this
basis, treatment of the aneurysmal disease cannot be considered
achieved, at least not from the conventional viewpoint of the endo-
vascular era, according to which treatment should stop blood ﬂow
outside the endograft and inside the aneurysm sac. And as we have
seen from our single case, the result of the event can be cata-
strophic; in other words, a lethal rupture may develop.3 Until605
